Clinical Study on the Efficacy of Bevacizumab in Combination with Pembrolizumab on Cellular Immune Function in the Treatment of Driver Gene-Negative Stage IV Lung Adenocarcinoma

PURPOSE: To explore the efficacy of bevacizumab in combination with PD-1 immune drug pembrolizumab on cellular immune function in the treatment of driver gene-negative stage IV lung adenocarcinoma and its short-term survival effect. METHODS: From February 2020 to December 2021, 85 patients with driv...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Jun, Gu, Juanjuan, Jiang, Lili, Zhao, Dongxia, Shao, Lili, Chen, Xi, Liu, Jianhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652087/
https://www.ncbi.nlm.nih.gov/pubmed/36385958
http://dx.doi.org/10.1155/2022/7298192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652087/
https://www.ncbi.nlm.nih.gov/pubmed/36385958
http://dx.doi.org/10.1155/2022/7298192

Ejemplares similares